Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant transaction on November 10, 2025, selling 93,471,204 shares at a price of $991.01 per share. This sale totaled approximately $92.6 billion.
Following this transaction, Lilly Endowment Inc retains an equivalent number of shares in Eli Lilly. The company, headquartered in Indianapolis, Indiana, is a key player in the pharmaceuticals industry, employing 47,000 full-time staff. Eli Lilly engages in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products, including those for cardiometabolic health, oncology, immunology, and neuroscience.
Eli Lilly's market capitalization stands at $962.2 billion, with a trailing P/E ratio of 52.26 and an EPS of 20.45. The company has a dividend yield of 59.0%. Upcoming earnings are expected on April 28, 2026, with an estimated EPS of $7.07 and revenue of $17.2 billion, followed by another report on August 4, 2026, projecting an EPS of $7.70 and revenue of $17.9 billion.
Insider transactions provide insight into the actions of company executives and board members, although they should not solely dictate investment decisions. Investors are encouraged to analyze patterns of insider activity over time and across multiple insiders to gain a more comprehensive view of market sentiment.